IQUIBICEN   23947
INSTITUTO DE QUIMICA BIOLOGICA DE LA FACULTAD DE CIENCIAS EXACTAS Y NATURALES
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Novel respirable rifampicin-curcumin loaded nanoparticles against Mycobacterium tuberculosis infection
Autor/es:
ALARCON LILIANA; RIEMER, CAROLINA; PELLEGRINI, JOAQUIN M.; GARCIA VERONICA; TATEOSIAN, NANCY L; ALARCON LILIANA; RIEMER, CAROLINA; PELLEGRINI, JOAQUIN M.; GARCIA VERONICA; TATEOSIAN, NANCY L; PALMAS LUCIA; DONNOLI, LUCIA; MORELLI, PAULA; BERNABEU, EZEQUIEL; MORETTON, MARCELA; PALMAS LUCIA; DONNOLI, LUCIA; MORELLI, PAULA; BERNABEU, EZEQUIEL; MORETTON, MARCELA; MARTINENA CAMILA; MARTIN CANDELA; RIEDEL, JENNIFER; AMIANO, NICOLÁS; CHIAPETTA, DIEGO; MARTINENA CAMILA; MARTIN CANDELA; RIEDEL, JENNIFER; AMIANO, NICOLÁS; CHIAPETTA, DIEGO
Reunión:
Congreso; Reunion de Sociedades de Biociencias 2020; 2020
Resumen:
Rifampicin (RIF) is one of the most powerful and effective first line drug employed in the treatment of Mycobacterium tuberculosis (Mtb) infection. With the worldwide emergence of highly drug-resistant tuberculosis (TB), novel agents that have direct antimycobacterial effects or that enhance host immunity are urgently needed. It was described the immunomodulatory anti-TB effects of Curcumin (CUR), a potent anti-oxidant and apoptosis inducer compound. We develop novel RIF-CUR nanoparticles (RIF-CUR NP) with improved drug aqueous solubility and stability for inhalator administration. Then, we analyzed by confocal microscopy the in vitro uptake of CUR-NP (20 µg/ml) in human macrophages (derived from PBMCs) at different time points (1h, 18h, 24h and 48h). We found a higher drug cellular uptake levels (intensity/ area) for Mtb antigen-stimulated cells (0.25±0.04) than unstimulated control (0.07±0.02) over 18 hours (ANOVA test, p